Outcome of COVID-19 Positive Patients with type 2 Diabetes and Polypharmacy: an Examination of a Tertiary Hospital Cohort
Clicks: 1
ID: 311525
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #222 of 254 articles by views in Yemen Journal of Medicine
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 254 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background: COVID-19-positive patients are at increased risk of adverse clinical outcomes, with type 2 diabetes cohorts at substantially higher risk compared to the general population. The additional role of diabetic and non-diabetic polypharmacy in these patients' clinical course has remained unexamined. In this study we have comprehensively examined the role of polypharmacy in the determination of mortality outcomes in patients with COVID-19 clinical syndrome.
Methods: We retrospectively examined case notes and electronic records of N = 497 patients with type 2 diabetes and COVID-19 infection. We ascertained the number of medications each patient was taking and used this to categorize the study cohort into diabetic [n = 246] (5 or more diabetic medications), and non-diabetic polypharmacy [n = 251] (5 or more non-diabetic medications). The primary outcome was the need for intensive care admission between the two groups.
Results: In patients with “non-diabetic polypharmacy” (>5 medications), advancing age, and higher HBA1c levels, were associated with increased risk of Intensive care admission (OR 1.06 [CI 1.03-1.07], P = <0001), (OR 1.01 [CI 1.01- 1.20], P 0.017), respectively. Patients taking 5 or more non-diabetic medications had an increased likelihood of admission into the intensive care unit compared to those on lower medication thresholds (OR = 1.7; CI = 1.1 to 1.3; p-value = <0.0006).
Conclusion: In an inpatient cohort of type 2 diabetic patients with COVID-19, non-diabetic polypharmacy was associated with a multiplicative risk of intensive care admissions. This will necessitate the need for periodic medication reviews.
| Reference Key |
danjuma2026outcome
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mohammed Danjuma, Bhagya Sree, Unwam jumbo, Lina Al Tarawneh, Rowan Mesilhy, Aly Roa, Hend AlObaidi, Amal H ElMasaad, Gamal AlFitori, Islam Elzouki, Lina Naseralallah |
| Journal | Yemen Journal of Medicine |
| Year | 2026 |
| DOI |
10.63475/yjm.v4i1.0051
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.